Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000592799 | SCV000709295 | uncertain significance | not provided | 2017-06-08 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000592799 | SCV003334991 | uncertain significance | not provided | 2022-04-01 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). ClinVar contains an entry for this variant (Variation ID: 502520). This variant has not been reported in the literature in individuals affected with VIPAS39-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces arginine, which is basic and polar, with proline, which is neutral and non-polar, at codon 409 of the VIPAS39 protein (p.Arg409Pro). |
Fulgent Genetics, |
RCV005010588 | SCV005635540 | uncertain significance | Arthrogryposis, renal dysfunction, and cholestasis 2 | 2024-05-31 | criteria provided, single submitter | clinical testing |